On the public citation graph

Drugs with breakthrough status charm investors

https://doi.org/10.1038/nbt1113-945
0 signed · 11 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3684095openalex-extracted
Competition Threats and Rival Innovation Responses: Evidence from Breakthrough Therapies
inferred← citeshttps://doi.org/10.2139/ssrn.3731669openalex-extracted
Regulating Ethical Experimentation: Impacts of the Breakthrough Therapy Designation on Drug R&D
inferred← citeshttps://doi.org/10.1016/b978-0-08-100625-2.00010-6openalex-snapshot
Drug discovery
inferred← citeshttps://doi.org/10.1016/b978-0-12-824304-6.00012-2openalex-snapshot
Drug discovery: Chaos can be your friend or your enemy
inferred← citeshttps://doi.org/10.1016/j.clinthera.2015.07.011openalex-snapshot
Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2023.102855openalex-snapshot
Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D
inferred← citeshttps://doi.org/10.1038/nbt.2864openalex-snapshot
A survey of breakthrough therapy designations
inferred← citeshttps://doi.org/10.1038/nbt1017-898openalex-snapshot
Speed and oversight: FDA Commissioner Gottlieb acts on pledges
inferred← citeshttps://doi.org/10.1093/rfs/hhae078openalex-snapshot
Competition and Innovation Revisited: A Project-Level View
inferred← citeshttps://doi.org/10.1111/1756-2171.12422openalex-snapshot
Does consumer demand pull scientifically novel drug innovation?
inferred← citeshttps://doi.org/10.2139/ssrn.4281959openalex-snapshot
Competition and Executive Compensation: Evidence from Pharmaceutical Breakthrough Designations
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.